Key result
Progressive drug-eluting stents remain key tools for treating CAD amid ongoing platform and coating developments.
Answers are grounded in this paper and cite their sources.
This review highlights the evolution of drug-eluting stents and future directions in stent platforms, coatings, and pharmacological agents for coronary artery disease.
The CYPHER (Cordis, Johnson & Johnson) sirolimus-eluting stent and the TAXU (Boston Scientific) paclitaxel-eluting stent have been extensively evaluated and have been proven to be significant novel tools for the treatment of coronary artery disease. Several sirolimus derivatives have already emerged, receiving CE Mark approval. However, in the future, it is likely that drugs presently under investigation will address additional mechanisms associated with neointimal formation, either as single agents or in combination with antiproliferative compounds. Concurrently, alterations on stent platform design (helicoidal, open-closed cell), coatings (biodegradable, bioabsorbable, nanoporous) and polymers are being explored.
No takes yet. Share an insight, caveat, or question.
Vaina et al. (2006) conducted a review in coronary artery disease. Progressive stent technologies (drug-eluting stents) was evaluated. Progressive stent technologies, including sirolimus- and paclitaxel-eluting stents, are significant tools for treating coronary artery disease, with ongoing developments in platforms and coatings.
Synapse has enriched 10 related papers. Consider them for comparative context: